Literature DB >> 571873

Cytoplasmic and nuclear progestin receptors in human myometrium during the menstrual cycle and in pregnancy at term.

G Giannopoulos, D Tulchinsky.   

Abstract

Exchange assays have been developed for the determination of the total progestin in receptor sites (unoccupied and occupied with endogenous hormone) in the cytosol and nuclei of human myometrium using radiolabeled R5020 (17,21-dimethyl-19-nor-4,9-pregnadiene-3,20-dione) as ligand. These assays have been applied to the measurement of cytosol and nuclear progestin receptor sites in the myometrium during the menstrual cycle and in pregnancy at term. Both the cytosol receptor levels as well as the sum of cytosol and nuclear receptor levels were highest during the proliferative phase of the cycle, dropped moderately but significantly in the secretory phase, and decreased markedly in pregnancy at term. Despite the marked drop in cytosol receptor levels, nuclear receptor levels in pregnancy at term were similar to those observed in the proliferative or secretory phase. In addition, the fraction of the total cellular receptor that was associated with the nucleus increased from 5.5% in the proliferative phase to 60% in pregnancy at term. The decrease in cytosol progestin receptor concentration as well as the relative increase in nuclear localization of the receptor in human myometrium in pregnancy at term may be related to the high circulating progesterone levels.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 571873     DOI: 10.1210/jcem-49-1-100

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  2 in total

1.  Contribution to the pathogenesis of dysmenorrhea.

Authors:  H P Zahradnik; M Breckwoldt
Journal:  Arch Gynecol       Date:  1984

2.  Endometrial estrogen and progesterone receptors within 2-14 days of missed menses in the human.

Authors:  K Garg; P Sujata; G L Kumari; P K Pandey; V Padubidri; C Anand
Journal:  J Endocrinol Invest       Date:  1993-04       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.